Tumor microenvironment (TME) is a specialized ecosystem of host components, designed
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …

The identification of actionable tumor antigens is indispensable for the development of
several cancer immunotherapies, including T cell receptor–transduced T cells and patient …

The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

Background Personalized immunotherapy utilizing cancer vaccines tailored to the tumors of
individual patients holds promise for tumors with high genetic heterogeneity, potentially …

Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …

Many tumour antigens that do not arise from cancer cell-specific mutations are targets of
humoral and cellular immunity despite their expression on non-malignant cells. Thus, in …

Background Clinically, prophylactic anti-recurrence treatments for hepatocellular carcinoma
(HCC) patients after radical surgery are extremely limited. Neoantigen based vaccine can …

Background The human leucocyte antigen (HLA) complex controls adaptive immunity by
presenting defined fractions of the intracellular and extracellular protein content to immune …

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly
because of the lack of actionable immune targets. Using an original proteogenomic …

Acute myeloid leukemia (AML), the most frequent leukemia in adults, is driven by recurrent
somatically acquired genetic lesions in a restricted number of genes. Treatment with tyrosine …